

2 August 2019

2019/20 Invitation to Tender

PHARMAC is seeking feedback from medical groups, DHB hospital pharmacies and other interested parties on:

- A proposal to tender certain pharmaceuticals for sole supply; and
- The draft process and terms and conditions for the 2019/20 Invitation to Tender (2019/20 Tender).

PHARMAC welcomes all feedback on the draft 2019/20 Tender. Feedback received by the deadline may be considered by the Tender Medical Evaluation Subcommittee of PTAC and would be considered by the PHARMAC Board (or its Delegate, where applicable) prior to making a decision on this proposal.

ALL RESPONSES ARE DUE BY 5 PM, FRIDAY 30 AUGUST 2019

Feedback should be provided by submitting an email or letter to the Tender Analysts:

Email: tender@pharmac.govt.nz

Letter: Tender Analysts
PHARMAC
PO Box 10-254
Wellington 6143

DDI: Emma Clarke (04) 830 1987
Nerissa Ramlall (04) 830 3824

Feedback we receive is subject to the Official Information Act 1982 (OIA) and we will consider any request to have information withheld in accordance with our obligations under the OIA. Anyone providing feedback, whether on their own account or on behalf of an organisation, and whether in a personal or professional capacity, should be aware that the content of their feedback and their identity may need to be disclosed in response to an OIA request.

We are not able to treat any part of your feedback as confidential unless you specifically request that we do, and then only to the extent permissible under the OIA and other relevant laws and requirements. If you would like us to withhold any commercially sensitive, confidential proprietary, or personal information included in your submission, please clearly state this in your submission and identify the relevant sections of your submission that you would like it withheld. PHARMAC will give due consideration to any such request.

Details of the proposed 2019/20 Tender

In accordance with PHARMAC's objective (to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided), PHARMAC is

consulting on a proposal to tender certain pharmaceuticals for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB hospital pharmacies.

Attached to this letter (as Schedule Two) is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply and/or Hospital Supply Status. Pharmaceuticals are sorted into therapeutic groups and then listed alphabetically in each group by chemical, form and strength. Each pharmaceutical has a 'C' and/or 'H' next to it to indicate whether it is proposed to be tendered for community and/or hospital supply.

In general, the proposed 2019/20 Tender process would be similar to the 2018/19 Tender. A copy of the draft 2019/20 Invitation to Tender is available on our website: www.pharmac.health.nz, or by contacting PHARMAC.

We are seeking feedback on the approach outlined in the following pages, in particular on:

- The proposed tender process and timeline;
- The actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule Two, including the impact of a brand switch on patients and clinical staff; and
- For hospital pharmaceuticals, your views on the appropriate Discretionary Variance (DV) Limit for each pharmaceutical, in the event you consider a 1% DV Limit to be clinically unacceptable.

Background

Since 1997 PHARMAC has been using the strategy of tendering pharmaceuticals for sole supply of pharmaceuticals for a fixed period of time. Regular tendering has proven to be an effective way to encourage competition among suppliers of pharmaceuticals. As in the past, the community and hospital tender processes would be run in unison, however, the pharmaceutical list for community and hospital supply may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For community pharmaceuticals, the tender winning brand would be the only subsidised brand for up to approximately 3 years. The Sole Subsidised Supply period would conclude on 30 June 2023 for all Tenders awarded from the 2019/20 Tender.
- No other brand of the pharmaceutical would be listed (or subsidised) in Section B of the Pharmaceutical Schedule during the Sole Subsidised Supply period.
- Other brands could continue to be marketed, sold and dispensed during the Sole Subsidised Supply Status period, but they would not receive a subsidy.
- Any pharmaceutical that currently carries a manufacturer's surcharge (that is, the additional patient charge above that of the patient co-payment) would become fully subsidised if a tender was awarded for that pharmaceutical.

Key Aspects of Awarding a Tender for DHB Hospital Pharmaceuticals:

- For DHB hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (subject to any allowance for alternative

brands under the agreed DV Limits) for up to approximately 3 years. The Hospital Supply Status period would conclude on 30 June 2023 for all tenders awarded from the 2019/20 Tender.

- No other brand of the pharmaceutical would be listed in Section H of the Pharmaceutical Schedule during the Hospital Supply Status period.

Key Dates and Timeframes for the 2019/20 Tender:

The proposed timelines for the 2019/20 Tender are as follows:

Date	Event
2 August 2019	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft 2019/20 Tender.
26 August 2019	Final date for receipt of Alternative Commercial Proposals (ACPs) to tendering by PHARMAC.
30 August 2019	Final date for all consultation to be received.
September 2019	PHARMAC considers feedback from consultation, negotiates with suppliers over any ACP proposals it considers would meet PHARMAC's Factors for Consideration, and enters into provisional contracts with suppliers where appropriate.
September 2019	Meeting of the Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
September/October 2019	Consultation and decisions on Alternative Commercial Proposals.
Early November 2019	Issuing of the 2019/20 Tender.
13 December 2019	Invitation to Tender closes.
From end of January 2020	Announcements on 2019/20 Tender decisions will commence.

Contractual obligations for suppliers

A copy of the draft terms and conditions which would form the terms of the 2019/20 Tender contract is available on the PHARMAC website: www.pharmac.health.nz.

Proposed inclusion of the following provisions in the 2019/20 Invitation to Tender

Supplier Code of Conduct

The New Zealand Government is committed to sustainable and inclusive government procurement and the Supplier Code of Conduct outlines the Government's expectations of suppliers in this respect.

PHARMAC expects suppliers to meet or exceed the minimum standards set out in the Supplier Code of Conduct and a provision has been included in Schedule 4 of the draft 2019/20 Tender as follows:

"You shall comply with the New Zealand Government's Supplier Code of Conduct (see <https://www.procurement.govt.nz/assets/procurement-property/documents/supplier-code-of-conduct.pdf>) ."

Additional Special Terms

PHARMAC proposes to include additional special terms in Schedule 7 of the 2019/20 Tender for the supply of lacosamide as follows.

In respect of the identified Tender Items in Schedule 2 (lacosamide (current access) tab 50 mg, 100 mg, 150 mg and/or 200 mg or lacosamide (widened access) tab 50 mg, 100 mg, 150 mg and/or 200 mg) (“Lacosamide Tender Items”) and notwithstanding any other provision in this Agreement concerning the Sole Supply Status of the Lacosamide Tender Items, and without limiting any other actions that it may be necessary or appropriate for PHARMAC to take in response to patient safety concerns, PHARMAC may grant subsidised access, on a strictly limited basis, to an alternative brand of the relevant Lacosamide Tender Items during the Sole Supply Period to the extent that this is necessary to enable a limited number of patients to continue treatment following adverse effects or efficacy concerns in their treatment with the relevant Lacosamide Tender Items, in accordance with the following condition:

The maximum number of patients who are treated with the alternative brand of Lacosamide Tender Items shall not exceed 30 patients per calendar year, unless otherwise agreed, during the Sole Supply Period.

For the avoidance of doubt, this clause does not apply to the lacosamide (current access) inj 10 mg per ml, 20 ml Tender Item.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the 2017/18 Tender and the 2018/19 Tender prior to issuing the 2019/20 Tender, and may close the tender for some of these tender items, and reissue them as part of the 2019/20 Tender. The following Tender Bids remain unresolved, and may potentially be added to the 2019/20 Tender following consultation:

2017/18 Invitation to Tender

Chemical Name	Line Item
Amoxicillin clavulanate	Grans for oral liq amoxicillin 400 mg with potassium clavulanate 57 mg per 5 ml
Bumetanide	Tab 1 mg
Chlorhexidine gluconate	Mouthwash 0.2%
Colchicine	Tab 500 mcg
Diclofenac sodium	Eye drops 0.1%
Dorzolamide hydrochloride	Eye drops 2%
Ibuprofen	Tab long-acting 800 mg
Lidocaine [lignocaine] hydrochloride with adrenaline	Inj 2% with adrenaline 1:80,000, 2.2 ml dental cartridge
Methotrexate	Inj 7.5 mg prefilled syringe

Chemical Name	Line Item
Methotrexate	Inj 10 mg prefilled syringe
Methotrexate	Inj 15 mg prefilled syringe
Methotrexate	Inj 20 mg prefilled syringe
Methotrexate	Inj 25 mg prefilled syringe
Methotrexate	Inj 30 mg prefilled syringe
Midodrine	Tab 2.5 mg
Methotrexate	Inj 15 mg prefilled syringe
Methotrexate	Inj 20 mg prefilled syringe
Methotrexate	Inj 25 mg prefilled syringe
Methotrexate	Inj 30 mg prefilled

Chemical Name	Line Item
	syringe
Midodrine	Tab 2.5 mg
Midodrine	Tab 5 mg
Mitozantrone	Inj 2 mg per ml, 10 ml

Chemical Name	Line Item
Norethisterone	Tab 5 mg
Oxycodone hydrochloride	Oral liq 1 mg per ml
Tobramycin	Solution for inhalation 60 mg per ml, 5 ml
Zoledronic acid	Inj 4 mg per 100 ml

2018/19 Invitation to Tender

Chemical Name	Line Item
Aciclovir	Eye oint 3%
Adapalene	Crm 0.1%
Adapalene	Gel 0.1%
Adenosine	Inj 3 mg per ml, 10 ml
Amoxicillin clavulanate	Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml
Amoxicillin clavulanate	Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml
Amoxicillin clavulanate	Inj 500 mg with clavulanic acid 100 mg
Amoxicillin clavulanate	Inj 1000 mg with clavulanic acid 200 mg
Anagrelide hydrochloride	Cap 0.5 mg
Beclomethasone Dipropionate	Metered aqueous nasal spray, 50 mcg per dose
Beclomethasone Dipropionate	Metered aqueous nasal spray, 100 mcg per dose
Bendamustine	Inj 25 mg vial
Bendamustine	Inj 100 mg vial
Bortezomib	Inj 3.5 mg
Brinzolamide	Eye drops 1%
Bupivacaine hydrochloride with fentanyl	Inj 1.25mg with 2 mcg fentanyl per ml, 15 ml syringe
Bupivacaine hydrochloride with fentanyl	Inj 1.25mg with 2 mcg fentanyl per ml, 20 ml syringe
Bupivacaine hydrochloride with fentanyl	Inj 0.625 mg with fentanyl 2 mcg per ml, 200 ml bag
Bupivacaine hydrochloride with glucose	Inj 0.5% with glucose 8%, 4 ml ampoule

Chemical Name	Line Item
Calcium folinate	Inj 50 mg
Calcium folinate	Inj 1 g
Capecitabine	Tab 500 mg
Capecitabine	Tab 150 mg
Captopril	Oral liq 5 mg per ml
Cefalexin monohydrate	Cap 500 mg
Chloramphenicol	Eye oint 1%
Cyclizine lactate	Inj 50 mg per ml, 1 ml
Dapsone	Tab 100 mg
Dapsone	Tab 25 mg
Doxorubicin	Inj 50 mg
Enalapril	Tab 5 mg
Enalapril	Tab 10 mg
Enalapril	Tab 20 mg
Ethambutol hydrochloride	Tab 100 mg
Ethambutol hydrochloride	Tab 400 mg
Fentanyl	inj 10 mcg per ml, 50 ml prefilled syringe
Fentanyl	inj 10 mcg per ml, 10 ml syringe
Fentanyl	inj 20 mcg per ml, 100 ml bag
Fluorouracil sodium	Inj 50 mg per ml, 50 ml
Ganciclovir	Inj 500 mg
Hydrocortisone	Inj 50 mg per ml, 2 ml
Hydrocortisone	Crm 1% (pack size greater than or equal to 15 g and less than or equal to 100 g)
Hydrocortisone	Crm 1% (pack size greater than 100 g)
Iron sucrose	Inj 20 mg per ml, 5 ml ampoule
Levonorgestrel	0.75 mg - 1.5 mg
Levosimendan	Inj 2.5 mg per ml, 5 ml
Lidocaine [Ligocaine] hydrochloride with	Gel 2% with 0.05% chlorhexidine, 10 ml

Chemical Name	Line Item
chlorhexidine	urethral syringe
Loperamide hydrochloride [split market]	Tab 2 mg
Loratadine	Oral liq 1 mg per ml
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 210 g sachet
Macrogol 3350 with ascorbic acid, potassium chloride and sodium chloride	Powder for oral soln 755.68 mg with ascorbic acid 85.16 mg, potassium chloride 10.55 mg, sodium chloride 37.33 mg and sodium sulphate 80.62 mg per g, 70 g sachet
Methylprednisolone aceponate	Crn 0.1%
Minocycline hydrochloride	Cap 100 mg
Minocycline hydrochloride	Tab 50 mg
Moxifloxacin	Inj 400 mg
Moxifloxacin	Tab 400 mg
Noradrenaline	Inj 0.06 mg per ml, 50 ml syringe
Noradrenaline	Inj 0.12 mg per ml, 100 ml bag
Noradrenaline	Inj 0.16 mg per ml, 50 ml syringe
Octreotide (somatostatin analogue)	LAR 10 mg pre-filled syringe
Octreotide (somatostatin analogue)	LAR 20 mg pre-filled syringe
Octreotide (somatostatin analogue)	LAR 30 mg pre-filled

Chemical Name	Line Item
analogue)	syringe
Olopatadine	Eye drops 0.1%
Ornidazole	Tab 500 mg
Pantoprazole	Inj 40 mg
Pegfilgrastim	Inj 6 mg per 0.6 ml prefilled syringe
Pemetrexed	Powder for infusion, 100 mg
Pemetrexed	Powder for infusion, 500 mg
Phenoxyethylpenicillin (Penicillin V)	Grans for oral liq 125 mg per 5 ml
Phenoxyethylpenicillin (Penicillin V)	Grans for oral liq 250 mg per 5 ml
Promethazine hydrochloride	Inj 25 mg per ml, 2 ml
Rocuronium bromide	Inj 10 mg per ml, 5 ml
Sodium chloride	Aqueous nasal spray isotonic
Sodium citrate	Oral liq 8.8% (300 mmol/l)
Sodium nitroprusside	Inj 50 mg
Spiroglactone	Tab 25 mg
Spiroglactone	Tab 100 mg
Sumatriptan	Inj 12 mg per ml, 0.5 ml
Tamsulosin [Current Access]	Tab 400 mcg
Tamsulosin [Widened Access]	Tab 400 mcg
Tenoxicam	Inj 20 mg
Teriparatide	Inj 250 mcg per ml
Tigecycline	Inj 50 mg
Tolcapone	Tab 100 mg
Urea	Crn 10%
Vitamin B complex (strong)	Tab
Zinc oxide	Powder

Should any unresolved Tender Bids be declined prior to the release of the 2019/20 Tender, PHARMAC would consider including those pharmaceuticals in the 2019/20 Tender. Currently unresolved Tender Bids have not been included in the draft pharmaceutical list set out in Schedule Two.

Distribution of Consultation Documents

Although this consultation letter has been widely distributed, should you consider that a particular person, group or agency should receive this letter and/or future tender documents, please feel free to contact PHARMAC or refer it on directly (note, all tender documents and consultations are also available from our website at www.pharmac.health.nz/news/consultation). We also invite any person or group to contact

PHARMAC should you wish to meet to discuss the proposals contained in this consultation letter.

Schedule Two: Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Schedule

Pharmaceuticals have been listed in groups according to the therapeutic group classification system used in the Pharmaceutical Schedule. Below is a list of these groups, and the corresponding page numbers for your ease of reference. Pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one group.

<i>Therapeutic Group</i>	Page Numbers
Alimentary Tract and Metabolism	9 - 11
Blood and Blood Forming Organs	11
Cardiovascular System	12 – 16
Dermatologicals	16 – 19
Extemporaneously Compounded Preparations	20
Genito-Urinary System	20 – 21
Hormone Preparations – Systemic excluding contraceptives	21 - 23
Infections – Agents for Systemic Use	23 – 27
Musculoskeletal System	27
Nervous System	27 – 33
Oncology and Immunosuppressants	33 – 35
Respiratory System and Allergies	35 – 36
Sensory Organs	36 – 37
Various	37

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 July 2019;
- the number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2019;
- an estimate of the annual community market value at current subsidies (estimated by multiplying the volume of units subsidised in the year ending 30 June 2019 by the relevant listed unit subsidy as at 1 July 2019); and
- comments specifically relating to the Tender Item and/or its current listing on the Pharmaceutical Schedule.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self-explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underlined	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2020 unless otherwise stated in the Comments column and a listing of a new brand could only occur after that date.
C	To be tendered for Sole Supply Status (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC's Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a patent.
*	There is no fully funded product available for this line item (in relation to community supply).
@	Additional Stock Pharmaceuticals (ASP) means a Pharmaceutical, marked with an "@", for which the supplier of the successful Tender Bid would be required to hold additional stock.
#	A rebate currently exists.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Alfacalcidol					
Cap 0.25 mcg	210,847	\$55,495	\$0.2632	C H 1%	
Cap 1 mcg	59,093	\$51,990	\$0.8798	C H 1%	
Oral drops 2 mcg per ml	14,240	\$43,204	\$3.0340	C H 1%	
Bismuth trioxide					
Tab	58,995	\$17,120	\$0.2902	C H 1%	Units and subsidy shown based on tab 120 mg presentation. All strengths reviewed as tender bids will be reviewed.
Budesonide (current access)					
Cap 3 mg modified release	347,257	\$642,425	\$1.8500	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Budesonide (widened access)					
Cap 3 mg modified release				C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Calcium carbonate					
Tab	7,608,693	\$228,869	\$0.0301	C H 1%	Preference for tab 1.25 g - 1.5 g.
Calcium Gluconate					
Inj 10%, 10 ml	769	\$2,461	\$3.2000	C H 1%	
Carmellose sodium					
Paste	25,888	\$7,871	\$0.3040 *	C H 1%	Preference for product containing gelatin and pectin. Units subsidy and cost shown is weighted.
Powder	1,288	\$390	\$0.3029	C H 1%	Preference for product containing gelatin and pectin.
Choline salicylate					
Oral gel	93,120	\$12,788	\$0.1373	C H 1%	
Citric acid with magnesium oxide and sodium picosulfate					
Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet				H 1%	
Colecalciferol					
Cap/Tab 1.25 mg	2,784,346	\$580,063	\$0.2083	C H 1%	
Diazoxide					
Cap 100 mg	5,620	\$15,736	\$2.8000	C H 1%	Current restrictions may apply.
Cap 25 mg	12,263	\$13,489	\$1.1000	C H 1%	Current restrictions may apply.
Oral liq 50 mg per ml	1,020	\$21,080	\$20.6667	C H 1%	Current restrictions may apply.
Docusate Sodium					
Tab 50 mg	624,983	\$14,437	\$0.0231	C H 1%	
Tab 120 mg	1,457,203	\$45,610	\$0.0313	C H 1%	
Gliclazide					
Tab 80 mg	27,065,762	\$557,013	\$0.0206	C H 1%	
Glucagon Hydrochloride					
Inj 1 mg syringe kit	20,608	\$659,456	\$32.0000	C H 1%	
Glucose [Dextrose]					
Gel 40%				H 1%	
Solution 15 g				H 1%	Not currently listed in the Pharmaceutical Schedule.
Tab 1.5 g				H 1%	
Tab 3.1 g				H 1%	
Tab 4 g				H 1%	
Glucose with sucrose and fructose					
Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet				H 1%	
Hydrocortisone Acetate					
Rectal foam 10%, CFC-free	196,019	\$246,649	\$1.2583	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Hydrogen peroxide						
Soln 3% (10 vol)	20,902	\$293	\$0.0140	C H	1%	Preference for pack size less than 200 ml. This product requires Medsafe registration prior to an award.
Hyoscine N-butylbromide						
Inj 20 mg, 1 ml	162,145	\$310,346	\$1.9140	C H	1%	
<u>Tab 10 mg</u>	5,812,813	\$508,621	\$0.0875	C H	1%	
Insulin isophane						
Inj insulin human 100 u per ml, 10 ml	47,080	\$83,237	\$1.7680	C H	1%	
Insulin neutral						
Inj human 100 u per ml, 10 ml	22,240	\$56,178	\$2.5260	C H	1%	
Insulin pen needles						
29 g x 12.7 mm	286,390	\$30,071	\$0.1050	C		
31 g x 5 mm	4,209,146	\$494,575	\$0.1175	C		
31 g x 6 mm	283,922	\$26,973	\$0.0950	C		
31 g x 8 mm	4,307,520	\$452,290	\$0.1050	C		
32 g x 4 mm	4,405,406	\$462,568	\$0.1050	C		
Insulin syringes, disposable with attached needle						
Syringe 0.3 ml with 29 g x 4 mm needle				C		Not currently listed in the Pharmaceutical Schedule.
Syringe 0.3 ml with 29 g x 6 mm needle				C		Not currently listed in the Pharmaceutical Schedule.
Syringe 0.5 ml with 29 g x 4 mm needle				C		Not currently listed in the Pharmaceutical Schedule.
Syringe 0.5 ml with 29 g x 6 mm needle				C		Not currently listed in the Pharmaceutical Schedule.
Syringe 1 ml with 29 g x 4 mm needle				C		Not currently listed in the Pharmaceutical Schedule.
Syringe 1 ml with 29 g x 6 mm needle				C		Not currently listed in the Pharmaceutical Schedule.
Syringe 0.3 ml with 29 g x 12.7 mm needle	12,879	\$1,674	\$0.1300	C	*	
Syringe 0.3 ml with 31 g x 8 mm needle	121,925	\$15,852	\$0.1300	C	*	
Syringe 0.5 ml with 29 g x 12.7 mm needle	39,079	\$5,081	\$0.1300	C	*	
Syringe 0.5 ml with 31 g x 8 mm needle	126,997	\$16,511	\$0.1300	C		
Syringe 1 ml with 29 g x 12.7 mm needle	25,069	\$3,260	\$0.1300	C		
Syringe 1 ml with 31 g x 8 mm needle	46,277	\$6,016	\$0.1300	C		
Iodine supplement						
Tab 150 mcg elemental	10,375,823	\$540,684	\$0.0521	C H	1%	
Ispaghula (psyllium) husk						
<u>Powder/granules</u>	84,651,000	\$1,024,277	\$0.0121	C H	1%	Units and unit subsidy shown are as per the 500 g presentation currently listed and expressed as 'per g'.
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride						
<u>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</u>	6,126,064	\$1,384,490	\$0.2260	C H	1%	May be subject to Special Authority restrictions.
Magnesium						
Cap/Tab (150 mg elemental)				H	1%	
Magnesium sulphate						
Inj 0.4 mmol per ml, 250 ml bag				H	1%	
<u>Inj 2 mmol per ml, 5ml</u>	21,314	\$21,762	\$1.0210	C H	1%	
Mebeverine hydrochloride						
Tab 135 mg	2,510,134	\$502,027	\$0.2000	C H	1%	
Mesalazine						
Tab long-acting 500 mg	9,331,739	\$5,510,392	\$0.5905	C H	1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Misoprostol					
Tab 200 mcg	51,124	\$17,680	\$0.3458	C H 1%	
Mucilaginous Laxatives					
<u>Dry</u>	84,651,000	\$1,024,277	\$0.0121	C H 1%	Not currently listed in Section H of the Pharmaceutical Schedule.
Nystatin					
<u>Oral liq 100,000 u per ml</u>	1,792,800	\$145,665	\$0.0813	C H 1%	
Omeprazole					
<u>Cap 10 mg</u>	6,454,257	\$141,994	\$0.0220	C H 1%	
<u>Cap 20 mg</u>	93,790,879	\$2,042,765	\$0.0218	C H 1%	
<u>Cap 40 mg</u>	27,452,284	\$951,771	\$0.0347	C H 1%	
Poloxamer					
<u>Oral drops 10%</u>	267,450	\$33,699	\$0.1260	C H 1%	
Pyridoxine hydrochloride					
<u>Tab 25 mg</u>	800,887	\$24,027	\$0.0300	C H 1%	
<u>Tab 50 mg</u>	1,713,683	\$46,715	\$0.0273	C H 1%	
Ranitidine hydrochloride					
Inj	23,156	\$40,523	\$1.7500	C H 1%	Units and subsidy shown are for inj 25 mg per ml, 2 ml presentation.
<u>Oral liq 150 mg per 10 ml</u>	1,929,098	\$33,045	\$0.0171	C H 1%	
<u>Tab 150 mg</u>	9,440,456	\$243,753	\$0.0258	C H 1%	
<u>Tab 300 mg</u>	2,761,040	\$100,557	\$0.0364	C H 1%	
Rifaximin					
<u>Tab 200 mg - 550 mg</u>	109,607	\$1,223,293	\$11.1607	C H 1%	Current restrictions may apply. Tab 550 mg is currently listed on the Pharmaceutical Schedule. Units shown are for tab 550 mg.
Sodium Acid Phosphate					
Enema 16% with sodium phosphate 8%	52,926	\$132,314	\$2.5000	C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Sodium alginate with magnesium alginate					
Powder for oral soln	974,019			C H 1%	Note this product is currently described as 'Alginic acid - sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet' in Section B of the Pharmaceutical Schedule.
Sodium alginate with sodium bicarbonate and calcium carbonate					
Oral liq	18,270,721	\$54,812	\$0.0030	C H 1%	Note this product is currently described as 'sodium alginate oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml'.
Tab 500 mg	520,054	\$15,602	\$0.0300	C H 1%	Note this product is currently described as sodium alginate tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg in Section B of the Pharmaceutical Schedule.
Thiamine hydrochloride					
Inj 100 mg per ml, 1 ml				H	
Tab 100 mg				C H 1%	Currently not listed in Section B of the Pharmaceutical Schedule.
<u>Tab 50 mg</u>	7,133,748	\$348,840	\$0.0489	C H 1%	
Inj 100 mg per ml, 2 ml				H 1%	
Triamcinolone acetonide					
<u>0.1% in Dental Paste USP</u>	133,395	\$142,199	\$1.0660	C H 1%	
Ursodeoxycholic acid					
<u>Cap 250 mg - 300 mg</u>	907,883	\$344,542	\$0.3795	C H 1%	Current restrictions may apply. Cap 250 mg is currently listed on the Pharmaceutical Schedule. Units shown are for cap 250 mg.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Alimentary Tract and Metabolism

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Vitamins					
Cap/tab (fat soluble vitamins A, D, E, K)	218,614	\$85,259	\$0.3900	C H 1%	Current restrictions may apply.
Tab (BPC cap strength)	16,594,283	\$174,240	\$0.0105	C H 1%	

Blood and Blood Forming Organs

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Glucose [Dextrose]					
<u>Inj 50%. 10 ml - 20 ml</u>	11,130	\$65,667	\$5.9000	C H 1%	Inj 50%, 10 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 10 ml ampoule.
<u>Inj 50%. 90 ml - 100 ml</u>	377	\$5,467	\$14.5000	C H 1%	Inj 50%, 90 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 90 ml ampoule.
Ticagrelor					
Tab 90 mg	3,199,974	\$5,142,806	\$1.6071 +	C H 1%	Current restrictions may apply.

Cardiovascular System

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Ajmaline					
Inj 50 mg per 10 ml				H 1%	
Alprostadil					
Inj 10 mcg				H 1%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.
Inj 20 mcg				H 1%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.
Ambrisentan (current access)					
Tab 10 mg	8,726	\$1,333,624	\$152.8333#	C H 1%	A confidential rebate applies. Longer transition periods may apply to this product. Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Tab 5 mg	2,064	\$315,448	\$152.8333#	C H 1%	A confidential rebate applies. Longer transition periods may apply to this product. Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Ambrisentan (widened access)					
Tab 10 mg				C H 1%	PHARMAC would only award a tender for either current or widened access
Tab 5 mg				C H 1%	PHARMAC would only award a tender for either current or widened access
Amiloride					
Tab 5 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Amiloride with Frusemide					
Tab 5 mg with frusemide 40 mg	130,984	\$40,370	\$0.3082	C H 1%	
Amiloride with Hydrochlorothiazide					
Tab 5 mg with hydrochlorothiazide 50 mg	776,892	\$77,689	\$0.1000	C H 1%	
Amlodipine					
<u>Tab 2.5 mg</u>	9,693,962	\$166,736	\$0.0172	C H 1%	
<u>Tab 5 mg</u>	19,075,798	\$254,090	\$0.0133	C H 1%	
<u>Tab 10 mg</u>	9,983,680	\$175,713	\$0.0176	C H 1%	
Bendroflumethiazide [Bendrofluazide]					
<u>Tab 2.5 mg</u>	18,669,512	\$466,738	\$0.0250	C H 1%	
<u>Tab 5 mg</u>	2,694,522	\$110,044	\$0.0408	C H 1%	
Bisoprolol Fumarate					
<u>Tab 2.5 mg</u>	7,453,023	\$292,308	\$0.0392	C H 1%	
<u>sole supply</u>					

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Bisoprolol Fumarate					
<u>Tab 5 mg</u>	4,265,927	\$244,096	\$0.0572	C H 1%	
<u>Tab 10 mg</u>	1,540,958	\$160,938	\$0.1044	C H 1%	
Captopril					
Oral liq 5 mg per ml	157,415	\$157,398	\$0.9999	C H 1%	Current restrictions may apply.
Carvedilol					
<u>Tab 12.5 mg</u>	2,299,938	\$88,157	\$0.0383	C H 1%	
<u>Tab 25 mg</u>	2,736,669	\$134,562	\$0.0492	C H 1%	
<u>Tab 6.25 mg</u>	2,410,457	\$89,982	\$0.0373	C H 1%	
Clonidine					
<u>TDDS 2.5 mg, 100 mcg per day</u>	53,888	\$99,693	\$1.8500	C H 1%	
<u>TDDS 5 mg, 200 mcg per day</u>	22,490	\$56,450	\$2.5100	C H 1%	
<u>TDDS 7.5 mg, 300 mcg per day</u>	15,264	\$47,089	\$3.0850	C H 1%	
Diazoxide					
Inj 15 mg per ml, 20 ml				H 1%	
Diltiazem hydrochloride					
Tab 30 mg	569,392	\$26,192	\$0.0460	C H 1%	
Tab 60 mg	248,826	\$21,150	\$0.0850	C H 1%	
Doxazosin mesylate					
<u>Tab 2 mg</u>	16,503,612	\$222,799	\$0.0135	C H 1%	
<u>Tab 4 mg</u>	12,247,469	\$222,659	\$0.0182	C H 1%	
Ephedrine					
Inj 3 mg per ml, 10 ml prefilled syringe				H 1%	
<u>Inj 30 mg per ml, 1ml</u>				H 1%	
Epoprostenol (current access)					
Inj 1.5 mg vial	330	\$24,159	\$73.2100	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Inj 500 mcg vial	30	\$1,098	\$36.6100	C H	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Epoprostenol (widened access)					
Inj 1.5 mg vial				C H 1%	PHARMAC would only award a tender for either current or widened access.
Inj 500 mcg vial				C H 1%	PHARMAC would only award a tender for either current or widened access.
Ezetimibe (current access)					
<u>Tab 10 mg</u>	7,156,369	\$477,115	\$0.0667	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Ezetimibe (widened access)					
Tab 10 mg				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of Special Authority criteria.
Ezetimibe with simvastatin (current access)					
Tab 10 mg with simvastatin 10 mg	59,038	\$10,135	\$0.1717	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Tab 10 mg with simvastatin 20 mg	93,135	\$19,093	\$0.2050	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Tab 10 mg with simvastatin 40 mg	200,811	\$47,859	\$0.2383	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Tab 10 mg with simvastatin 80 mg	167,507	\$45,507	\$0.2717	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Ezetimibe with simvastatin (widened access)					
Tab 10 mg with simvastatin 10 mg				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Tab 10 mg with simvastatin 20 mg				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Tab 10 mg with simvastatin 40 mg				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Tab 10 mg with simvastatin 80 mg				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Gemfibrozil					
Tab 600 mg	386,478	\$125,992	\$0.3260	C H 1%	
Glyceryl trinitrate					
Spray 400 mcg per dose	1,515,650	\$33,723	\$0.0223	C H 5%	
Inj 1 mg per ml, 5 ml - 10 ml				H 1%	
Inj 5 mg per ml, 10 ml				H 1%	
Indapamide					
Tab 2.5 mg	1,491,369	\$43,086	\$0.0289	C H 1%	
Isosorbide mononitrate					
<u>Tab 20 mg</u>	519,256	\$97,620	\$0.1880	C H 1%	
Tab long-acting 40 mg	613,287	\$153,322	\$0.2500	C H 1%	
<u>Tab long-acting 60 mg</u>	7,038,578	\$648,323	\$0.0921	C H 1%	
Ivabradine (current access)					
Tab 5 mg				H 1%	
Ivabradine (widened access)					
Tab 5 mg				H 1%	PHARMAC would only award a tender for either current or widened access.
Losartan					
<u>Tab 12.5 mg</u>	2,985,540	\$49,411	\$0.0166	C H 1%	
<u>Tab 25 mg</u>	5,753,456	\$111,617	\$0.0194	C H 1%	
<u>Tab 50 mg</u>	9,430,953	\$224,551	\$0.0238	C H 1%	
<u>Tab 100 mg</u>	4,995,536	\$137,377	\$0.0275	C H 1%	
Metaraminol tartrate					
Inj 0.5 mg per ml, 10 ml				H 1%	Not currently listed in the Pharmaceutical Schedule.
Inj 0.5 mg per ml, 20 ml prefilled syringe				H 1%	
Inj 0.5 mg per ml, 6 ml				H 1%	Not currently listed in the Pharmaceutical Schedule.
Inj 1 mg per ml, 1 ml				H 1%	
Inj 1 mg per ml, 10 ml prefilled syringe				H 1%	
Inj 10 mg per ml, 1 ml				H 1%	
Nicardipine hydrochloride (current access)					
Inj 2.5 mg per ml, 10 ml vial				H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Nicardipine hydrochloride (widened access)					
Inj 2.5 mg per ml, 10 ml vial				H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of the restriction to paediatric patients only.
Nicotinic acid					
<u>Tab 50 mg</u>	581,959	\$23,977	\$0.0412	C H 1%	
<u>sole supply</u>					

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Nicotinic acid						
<u>Tab 500 mg</u>	496,432	\$88,812	\$0.1789		C H 1%	
Nifedipine						
<u>Tab long-acting 10 mg</u>	803,651	\$142,383	\$0.1772		C H 1%	
Tab long-acting 20 mg	603,119	\$57,839	\$0.0959		C H 1%	
<u>Tab long-acting 30 mg</u>	601,723	\$62,982	\$0.1047		C H 1%	
<u>Tab long-acting 60 mg</u>	173,501	\$32,792	\$0.1890		C H 1%	
Noradrenaline						
Inj 0.06 mg per ml, 100 ml bag					H 1%	
Inj 0.1 mg per ml, 100 ml bag					H 1%	
Inj 0.1 mg per ml, 50 ml syringe					H 1%	Not currently listed on the Pharmaceutical Schedule.
Inj 0.12 mg per ml, 50 ml syringe					H 1%	
Inj 1 mg per ml, 100 ml bag					H 1%	
Perindopril						
Tab 2 mg - 2.5 mg	838,001	\$104,750	\$0.1250		C H	Units and subsidy shown are tab 2 mg presentation. Bids for erbumine and/or arginine salts will be considered. Preference for the same salt across all strengths.
Tab 4 mg - 5 mg	1,692,676	\$270,828	\$0.1600		C H	Units and subsidy shown are per tab 4 mg presentation. Bids for erbumine and/or arginine salts will be considered. Preference for the same salt across all strengths.
Tab 8 mg - 10 mg					C H	Not currently listed in the Pharmaceutical Schedule. Bids for erbumine and/or arginine salts will be considered. Preference for the same salt across all strengths.
Phenoxybenzamine						
Cap 10 mg	20,424	\$44,252	\$2.1667		C H 1%	
Phenoxybenzamine hydrochloride						
Inj 50 mg per ml, 2 ml ampoule					H 1%	
Phentolamine Mesylate						
Inj 10 mg per ml, 1 ml					H 1%	
Inj 5 mg per ml, 1 ml					H 1%	
Phenylephrine hydrochloride						
Inj 10 mg per ml, 1 ml					H 1%	
Pravastatin						
Tab 10 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 20 mg</u>	3,394,331	\$160,212	\$0.0472		C H 1%	
<u>Tab 40 mg</u>	1,706,545	\$137,547	\$0.0806		C H 1%	
Prazosin Hydrochloride						
Tab 1 mg	536,269	\$29,656	\$0.0553		C H 1%	
Tab 2 mg	299,476	\$20,963	\$0.0700		C H 1%	
Tab 5 mg	104,459	\$12,222	\$0.1170		C H 1%	
Propafenone hydrochloride						
Tab 150 mg	70,212	\$57,433	\$0.8180		C H 1%	
Rosuvastatin						
Tab 5 mg					C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.
Tab 10 mg					C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Cardiovascular System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Rosuvastatin						
Tab 20 mg				C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.	
Tab 40 mg				C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.	
Selexipag						
Tab 200 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 400 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 600 mcg						
Tab 800 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1000 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1200 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1400 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1600 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Simvastatin						
<u>Tab 10 mg</u>	3,905,690	\$41,244	\$0.0106	C H 1%		
<u>Tab 20 mg</u>	17,783,874	\$300,370	\$0.0169	C H 1%		
<u>Tab 40 mg</u>	15,672,177	\$457,941	\$0.0292	C H 1%		
<u>Tab 80 mg</u>	1,054,633	\$70,312	\$0.0667	C H 1%		
Tadalafil						
Tab/Cap 2.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Tab/Cap 5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Tab/Cap 10 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Tab/Cap 20 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Terazosin hydrochloride						
Tab 1 mg	893,747	\$18,831	\$0.0211	C H 1%		
Tab 2 mg	4,311,188	\$64,668	\$0.0150	C H 1%		
Tab 5 mg	3,140,339	\$68,459	\$0.0218	C H 1%		
Timolol						
Tab 10 mg	53,282	\$5,621	\$0.1055	C H 1%	This is listed in Section H of the Pharmaceutical Schedule as timolol maleate.	
Verapamil hydrochloride						
Inj 2.5 mg per ml, 2 ml	2,481	\$12,405	\$5.0000	C H 1%		
Tab 40 mg	231,750	\$16,246	\$0.0701	C H 1%		
Tab 80 mg	88,072	\$10,340	\$0.1174	C H 1%		

Dermatologicals

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Acitretin						
<u>Cap 10 mg</u>	483,243	\$143,847	\$0.2977	C H 1%	Special Authority restrictions may apply. There may be a preference for a blister pack.	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Acitretin					
<u>Cap 25 mg</u>	110,664	\$76,284	\$0.6893	C H 1%	Special Authority restrictions may apply. There may be a preference for a blister pack.
Amorolfine					
<u>Nail soln 5%</u>	102,145	\$325,843	\$3.1900	C H 1%	
Benzoyl peroxide					
Soln/Gel/Cream/Lotion 5%				C H 1%	Note this product may require Medsafe registration prior to an award. Not currently listed in Section B of the Pharmaceutical Schedule.
Betamethasone Dipropionate					
Crm 0.05% (pack size 30 g or less)				H 1%	
Crm 0.05% (pack size greater than 30 g)	295,950	\$58,400	\$0.1973	C H 1%	
Crm 0.05% in propylene glycol base	195,450	\$28,209	\$0.1443	C H 1%	
Oint 0.05% (pack size 30 g or less)				H 1%	
Oint 0.05% (pack size greater than 30 g)	329,460	\$65,012	\$0.1973	C H 1%	
Oint 0.05% in propylene glycol base	22,995	\$3,319	\$0.1443	C H 1%	
Calamine					
Lotn, BP	3,546,827	\$22,948	\$0.0065	C H 1%	Preference for a 200 ml pack or less. Note this product requires Medsafe registration prior to an award.
Calcipotriol					
<u>Oint 50 mcg per g</u>	1,488,200	\$669,690	\$0.4500	C H 1%	
Calcium Gluconate					
Gel 2.5%				H 1%	Preference for a pack size of 40 g - 100 g
Chlorhexidine gluconate					
Soln 4%	2,358,497	\$18,774	\$0.0080	C H 1%	500mL pump preferred. Note that this product requires Medsafe registration prior to an award.
Clobetasone butyrate					
Crm 0.05% (pack size 30 g or less)	450,780	\$80,838	\$0.1793	C H 1%	
Clotrimazole					
<u>Crm 1%</u>	3,523,060	\$123,307	\$0.0350	C H 1%	
Soln 1%	13,240	\$2,886	\$0.2180	C H 1%	
Diflucortolone Valerate					
Crm 0.1%	87,600	\$15,715	\$0.1794	C H 1%	
Fatty oint 0.1%	101,550	\$18,218	\$0.1794	C H 1%	
Econazole Nitrate					
Crm 1%	26,780	\$1,339	\$0.0500	C H 1%	
Foaming soln 1%, 10 ml sachets	59,486	\$196,106	\$3.2967	C H 1%	
Emulsifying ointment					
Oint BP (pack size of 200 g or less)				H 1%	
<u>Oint BP (pack size greater than 200 g)</u>	38,879,455	\$279,154	\$0.0072	C H 1%	
Hydrocortisone					
<u>Powder</u>	54,663	\$109,217	\$1.9980	C H 1%	Current restrictions may apply. Note this product requires Medsafe registration prior to an award.
Hydrocortisone butyrate					
Cream/lipocream 0.1% (pack size 30 g or less)	1,782,150	\$122,077	\$0.0685	C H 1%	
Cream/lipocream 0.1% (pack size greater than 30 g)	21,082,000	\$2,403,348	\$0.1140	C H 1%	
Hydrocortisone with wool fat and mineral oil					
<u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	10,698,213	\$452,320	\$0.0423	C H 1%	Preference for a pack size of 300 g or less.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Hydrogen Peroxide						
Crn 1%	2,416,630	\$1,706,701	\$0.7062 #	C H 1%	Preference for a pack size of 50 g or more. Preference for tube packaging. Unit subsidy shown is weighted. This product requires Medsafe registration prior to an award.	
Imiquimod						
Crn 5%	466,774	\$422,430	\$0.9050	C H 1%	Units are per sachet	
Ivermectin						
Tab 3 mg	12,656	\$54,421	\$4.3000	C H 1%	Current restrictions may apply.	
Ketoconazole						
Shampoo 2%	6,161,300	\$184,223	\$0.0299	C H 1%	Current restrictions may apply.	
Malathion						
Lotn 0.5%				H 1%		
Shampoo 1%				H 1%		
Menthol						
Crystals	35,997	\$10,655	\$0.2960	C H 1%	Current restrictions may apply.	
Methylprednisolone aceponate						
Crn 0.1%	664,920	\$219,424	\$0.3300	C H 1%		
Oint 0.1%	380,565	\$125,586	\$0.3300	C H 1%		
Metronidazole						
Gel 0.75%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Special Authority restrictions for use on odiferous wounds only may apply.	
Miconazole nitrate						
Crn 2% (15 g - 20 g pack)	2,767,860	\$136,539	\$0.0493	C H 1%		
Lotn/tincture 2%	25,080	\$3,645	\$0.1453	C H 1%		
Mupirocin						
Intra-nasal oint 2%				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply.	
Topical oint 2% (pack size 5 g or less)	311,055	\$136,864	\$0.4400	C H 1%	Current restrictions may apply.	
Permethrin						
Crn 5%	814,350	\$134,368	\$0.1650	C H 1%		
Lotion 5%	1,713,960	\$210,817	\$0.1230	C H 1%		
Phenothrin						
Shampoo 0.5%	4,537,800	\$257,747	\$0.0568 #	C H 1%		
Pimecrolimus						
Crn 1%				C H 1%	PHARMAC reserves the right to award tenders for one, some or all presentations of topical tacrolimus or pimecrolimus. This item is not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	
Pine tar with triethanolamine lauryl sulphate and fluorescein						
Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium	30,521,428	\$235,625	\$0.0077	C H 1%		
Podophyllotoxin						
Soln 0.5%	10,735	\$103,051	\$9.6000	C H 1%		
Potassium permanganate						
Crystals/Tab				H 1%	Note this product may require Medsafe registration prior to an award.	
Povidone Iodine						
Oint 10%	601,920	\$78,731	\$0.1308	C H 1%		
Skin preparation, povidone iodine 10% with 30% alcohol (pack size 100 ml or less)	3,300	\$54	\$0.0163 *	C H 1%	Not currently listed in Section H of the Pharmaceutical Schedule.	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Dermatologicals

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments
Povidone Iodine						
Skin preparation, povidone iodine 10% with 30% alcohol (pack size greater than 100 ml)	75,275	\$1,506	\$0.0200	C H	1%	
Skin preparation, povidone iodine 10% with 70% alcohol	220,400	\$3,593	\$0.0163 #	C H	1%	
Salicylic Acid						
Powder	271,534	\$20,506	\$0.0755	C H	1%	Note this product may require Medsafe registration prior to an award.
Silver Sulphadiazine						
<u>Crn 1% (pack size of 100 g or less)</u>	506,200	\$109,339	\$0.2160	C H	1%	Crn 1% 50 g is currently listed on the Pharmaceutical Schedule. Units shown are for crn 1% 50 g.
Tacrolimus						
Oint 0.03%				C H	1%	PHARMAC reserves the right to award tenders for one, some or all presentations of topical tacrolimus or pimecrolimus. This item is not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Oint 0.1%				C H	1%	PHARMAC reserves the right to award tenders for one, some or all presentations of topical tacrolimus or pimecrolimus. This item is not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Triamcinolone acetonide						
<u>Crn 0.02%</u>	2,382,200	\$150,079	\$0.0630	C H	1%	
<u>Oint 0.02%</u>	1,383,800	\$87,871	\$0.0635	C H	1%	
Triclosan						
Soln 1%	2,117,000	\$24,981	\$0.0118	C		Preference for pack size of 500 ml or less. Subsidy by endorsement only. Note this product may require Medsafe registration prior to an award.
Wool fat with mineral oil						
Lotn hydrous 3% with mineral oil, 1000 ml	1,013,381	\$5,675	\$0.0056 *	C		
Lotn hydrous 3% with mineral oil, 250 ml	1,408,000	\$7,885	\$0.0056 *	C H	1%	Not currently listed in Section H of the Pharmaceutical Schedule.
Zinc						
Crn (pack size 50 g or less)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Crn (pack size greater than 50 g)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Oint (pack size 50 g or less)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Oint (pack size greater than 50 g)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Paste (pack size 50 g or less)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Zinc and castor oil						
Crn (pack size 50 g or less)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Crn (pack size greater than 50 g)				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Oint 5% (pack size 50 g or less)</u>				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Oint 5% (pack size greater than 50 g)</u>	19,156,765	\$162,832	\$0.0085	C H	1%	Units and subsidy shown are per the 500 g pack size currently listed.

Extemporaneously Compounded Preparations

Chemical Name					DV	
Line Item	Units	Cost	Unit Subsidy		Limit	Comments

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Extemporaneously Compounded Preparations

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Glycerol					
<u>Liq BP</u>	1,432,643	\$9,398	\$0.0066	C H 1%	There may be a preference for a pack size of 500 mL or less.
Magnesium hydroxide					
Paste/oral liq	480,586	\$21,732	\$0.0452	C H 1%	Note units and unit subsidy expressed are for the paste presentation.

Genito-Urinary System

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Carboprost					
Inj 250 mcg per ml, 1ml				H 1%	
Chlorhexidine gluconate					
Crm 1% obstetric				H 1%	Preference for a small tube for single use, under 100 g. Note that this product requires Medsafe registration prior to an award.
Lotn 1% obstetric				H 1%	Note that this product requires Medsafe registration prior to an award.
Condoms					
Female, non-latex				C	Not currently listed in Section B of the Pharmaceutical Schedule.
Male 55 mm - 58 mm, non-latex				C	Not currently listed in Section B of the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cyproterone acetate with ethinyloestradiol					
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	10,692,612	\$297,255	\$0.0278	C H 1%	
Dinoprostone					
Gel 1 mg				H 1%	
Gel 2 mg				H 1%	
Ergometrine maleate					
Inj 250 mcg per ml, 1 ml ampoule	200			C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	1,140	\$23,940	\$21.0000	C H 1%	
Ethinyloestradiol with Desogestrel					
Tab 20 mcg with desogestrel 150 mcg	284,704	\$22,438	\$0.0788	C H 1%	
Tab 30 mcg with desogestrel 150 mcg	274,652	\$21,645	\$0.0788	C H 1%	
Ethinyloestradiol with levonorgestrel					
<u>Tab 20 mcg with levonorgestrel 100 mcg</u>	6,957,468	\$180,487	\$0.0259	C H 1%	Note units and unit subsidy expressed are based on a product inclusive of 7 inert tablets (per month).
<u>Tab 30 mcg with levonorgestrel 150 mcg</u>	27,088,040	\$570,858	\$0.0211	C H 1%	Note units and unit subsidy expressed are based on a product inclusive of 7 inert tablets (per month).
Tab 50 mcg with levonorgestrel 125 mcg	399,868	\$44,985	\$0.1125	C H 1%	Note units and unit subsidy expressed are based on a product inclusive of 7 inert tablets (per month).
Finasteride					
<u>Tab 5 mg</u>	4,438,091	\$213,472	\$0.0481	C H 1%	Preference for a blister pack. May be subject to Special Authority restrictions.
Levonorgestrel					
<u>Subdermal implant</u>	14,402	\$1,539,862	\$106.9200	C H 1%	Longer transition periods may apply to this product. Training should be provided to clinicians if awarded.
Medroxyprogesterone Acetate					
Inj 150 mg per ml, 1 ml	155,810	\$1,129,623	\$7.2500	C H 1%	
Miconazole nitrate					
<u>Vaginal crm 2% with applicator</u>	436,040	\$42,296	\$0.0970	C H 1%	Single use applicators preferred.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Genito-Urinary System

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Mifepristone						
Tab 200 mg				H 1%		
Nystatin						
<u>Vaginal crm 100,000 u per 5 g with applicator(s)</u>	137,100	\$8,134	\$0.0593	C H 1%	Units and unit subsidy expressed as 'per g'.	
Oestriol						
<u>Crn 1 mg per g with applicator(s)</u>	2,988,540	\$1,318,932	\$0.4413	C H 1%	Applicator(s) should be multiple use and a measured dose.	
<u>Pessaries 500 mcg</u>	375,994	\$171,953	\$0.4573	C H 1%		
Ortho-Tolidine						
Compound diagnostic sticks			\$0.1500	C		
Oxybutynin						
Oral liq 1 mg per ml	425,620	\$54,352	\$0.1277	C H 1%	Preference for pack size 500 ml or less	
Tab 5 mg	7,771,036	\$137,547	\$0.0177	C H 1%		
Potassium citrate						
Tab				C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.	
Pregnancy tests - HCG urine						
Pregnancy test - HCG urine - Dipstick				C	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine.	
<u>Pregnancy tests - HCG urine - Cassette</u>	428,240	\$128,472	\$0.3000	C	PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine.	
Pregnancy tests - HCG urine - Midstream				C	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine.	
Sodium Citro-Tartrate						
<u>Grans effervescent 4 g sachets</u>	2,233,544	\$186,657	\$0.0836	C H 1%		
Tolterodone tartrate						
Tab 1 mg	172,085	\$44,742	\$0.2600	C H 1%	Special Authority restrictions may apply.	
Tab 2 mg	186,880	\$48,589	\$0.2600	C H 1%	Special Authority restrictions may apply.	
Water-based lubricant						
Single use sachets, 4 ml/g or larger				C	Not currently listed in Section B of the Pharmaceutical Schedule. Restrictions may apply. Preference for a small pack size.	

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Betamethasone						
Inj 4 mg per ml, 1 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Tab 500 mcg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Betamethasone Sodium Phosphate with Betamethasone Acetate						
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml	1,477	\$5,672	\$3.8400	C H 1%		
Buserelin Acetate						
Inj 1 mg per ml, 5.5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Carbimazole						
Tab 5 mg	4,364,939	\$471,413	\$0.1080	C H 1%		
Danazol						
Cap 100 mg	17,703	\$12,096	\$0.6833	C H 1%		

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Danazol					
Cap 200 mg	9,996	\$9,779	\$0.9783	C H 1%	
Desmopressin					
Inj 15 mcg per ml, 1 ml				H 1%	
Inj 4 mcg per ml, 1 ml	4,984	\$33,483	\$6.7180	C H 1%	Current restrictions may apply.
Nasal drops 100 mcg per ml	6,093	\$95,116	\$15.6120	C H 1%	
<u>Nasal spray 10 mcg per dose</u>	87,816	\$350,532	\$3.9917	C H 1%	
Tab 100 mcg	92,684	\$77,236	\$0.8333	C H 1%	Current restrictions may apply.
Tab 200 mcg	38,877	\$70,562	\$1.8150	C H 1%	Current restrictions may apply.
Fludrocortisone Acetate					
Tab 100 mcg	1,342,549	\$192,253	\$0.1432	C H 1%	
Gestrinone					
Cap 2.5 mg				H 1%	
Goserelin					
Implant 10.8 mg, syringe	22,220	\$3,944,050	\$177.5000	C H 1%	
Implant 3.6 mg, syringe	7,886	\$524,261	\$66.4800	C H 1%	
Iodine					
Soln aqueous BP				H 1%	
Medroxyprogesterone acetate					
Tab 2.5 mg	664,389	\$83,049	\$0.1250	C H 1%	
Tab 5 mg	806,272	\$112,878	\$0.1400	C H 1%	
Tab 10 mg	1,712,373	\$408,110	\$0.2383	C H 1%	
Tab 100 mg	23,739	\$23,976	\$1.0100	C H 1%	Not currently listed in Section H of the Pharmaceutical Schedule.
Metyrapone					
Cap 250 mg	27,790	\$289,016	\$10.4000	C	
Oestradiol					
Tab 1 mg	356,944	\$52,521	\$0.1471 *	C H 1%	
Tab 2 mg	241,640	\$35,555	\$0.1471 *	C H 1%	
TDDS 25 mcg per day	276,743	\$211,708	\$0.7650	C H 1%	
TDDS 50 mcg per day	350,086	\$308,076	\$0.8800	C H 1%	
TDDS 75 mcg per day	61,877	\$61,181	\$0.9888	C H 1%	
TDDS 100 mcg per day	115,917	\$114,613	\$0.9888	C H 1%	
Oestradiol with norethisterone					
Tab 1 mg with 0.5 mg norethisterone acetate	943,404	\$181,945	\$0.1929	C H 1%	
Tab 2 mg with 1 mg norethisterone acetate	373,408	\$72,015	\$0.1929	C H 1%	
Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg (oestradiol tab (12) and 1 mg oestradiol tab (6)	199,108	\$38,400	\$0.1929	C H 1%	
Oestriol					
<u>Tab 1 mg - 2 mg</u>	200,214	\$46,716	\$0.2333	C H 1%	Units and unit subsidy are based per 2 mg tablet. Preference for 2 mg tablets to be scored.
Oestrogens					
Conjugated, equine tab 300 mcg	299,986	\$32,248	\$0.1075	C H 1%	
Conjugated, equine tab 625 mcg	360,416	\$53,032	\$0.1471	C H 1%	
Prednisone					
<u>Tab 1 mg</u>	11,419,671	\$243,924	\$0.0214	C H 1%	
<u>Tab 2.5 mg</u>	2,178,215	\$52,669	\$0.0242	C H 1%	
<u>Tab 20 mg</u>	6,366,606	\$369,645	\$0.0581	C H 1%	
<u>Tab 5 mg</u>	12,681,001	\$281,265	\$0.0222	C H 1%	
Progesterone					
Cap 100 mg	40,563	\$22,310	\$0.5500	C H 1%	Must be compatible for intra-vaginal use. Current restrictions may apply. PHARMAC reserves the right to amend access.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Propylthiouracil					
Tab 50 mg	243,313	\$85,160	\$0.3500	C H 1%	Current restrictions may apply.
Terlipressin					
Inj 0.1 mg per ml, 8.5 ml ampoule				H 1%	
Inj 1 mg per 8.5 ml ampoule				H 1%	
Testosterone cypionate					
<u>Inj long-acting 100 mg per ml, 10 ml</u>	1,643	\$125,690	\$76.5000	C H 1%	
Thyrotropin alfa					
Inj 900 mcg vial				H 1%	
Triamcinolone acetonide					
<u>Inj 10 mg per ml, 1 ml</u>	4,196	\$17,455	\$4.1600	C H 5%	PHARMAC reserves the right to list a preservative free product for a restricted market.
<u>Inj 40 mg per ml, 1 ml</u>	76,398	\$780,788	\$10.2200	C H 1%	PHARMAC reserves the right to list a preservative free product for a restricted market.

Infections

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Albendazole					
Tab	728	\$5,693	\$7.8200	C H 1%	Current restrictions may apply. Note units and unit subsidy corresponds to the currently listed tab 400 mg presentation. All strengths received as tender bids will be reviewed.
Amikacin					
Inj 15 mg per ml				H 1%	Current restrictions may apply.
Inj 5 mg per ml				H 1%	Current restrictions may apply.
Amoxicillin					
<u>Grans for oral liq 125 mg per 5 ml</u>	10,717,993	\$128,616	\$0.0120	C H 1%	Preference may be given to products which include a measuring device.
<u>Grans for oral liq 250 mg per 5 ml</u>	52,349,459	\$685,778	\$0.0131	C H 1%	Preference may be given to products which include a measuring device.
<u>Inj 250 mg</u>	83	\$89	\$1.0670	C H 1%	
<u>Inj 500 mg</u>	1,039	\$1,289	\$1.2410	C H 1%	
<u>Inj 1 g</u>	6,575	\$11,368	\$1.7290	C H 1%	
Amoxicillin clavulanate					
<u>Tab amoxicillin 500 mg with potassium clavulanate 125 mg</u>	12,430,916	\$1,168,506	\$0.0940	@ C H 1%	
Amphotericin B					
Inj 50 mg (non-liposomal)				H 1%	Current restrictions may apply.
Liposomal inj 50 mg				H 1%	Current restrictions may apply.
Aztreonam					
Inj 1 g				H 1%	Current restrictions may apply.
Benzympenicillin sodium [Penicillin G]					
<u>Inj 600 mg</u>	6,996	\$7,241	\$1.0350	C H 1%	
Cefazolin sodium					
<u>Inj 500 mg</u>	130	\$88	\$0.6780	C H 1%	
<u>Inj 1 g</u>	25,845	\$17,006	\$0.6580	C H 1%	
Cefotaxime					
Inj 500 mg				H 1%	
Inj 1 g				H 1%	
Cefoxitin Sodium					
Inj 1 g				H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Ceftaroline fosamil					
Inj 600 mg vial				H 1%	Current restrictions may apply.
Ceftazidime					
Inj 1 g				H 1%	Current restrictions may apply.
Cefuroxime sodium					
<u>Inj 750 mg</u>				H 1%	
<u>Inj 1.5 g</u>				H 1%	
Chloramphenicol					
Inj 1 g				H 1%	Current restrictions may apply.
Chloroquine phosphate					
Tab 250 mg				H 1%	Current restrictions may apply.
Cidofovir					
Inj 75 mg per ml, 5 ml				H 1%	Current restrictions may apply.
Ciprofloxacin					
<u>Tab 250 mg</u>	183,732	\$9,515	\$0.0518	C H 1%	
<u>Tab 500 mg</u>	1,047,036	\$74,413	\$0.0711	C H 1%	
<u>Tab 750 mg</u>	24,706	\$2,779	\$0.1125	C H 1%	
Clarithromycin					
Inj 500 mg				H 1%	Current restrictions may apply.
<u>Tab 250 mg</u>	151,953	\$43,199	\$0.2843	C H 1%	Current restrictions may apply.
<u>Tab 500 mg</u>	127,685	\$94,852	\$0.7429	C H 1%	Current restrictions may apply.
Colistin Sulphomethate					
Inj 150 mg	6,133	\$398,645	\$65.0000	C H 1%	Current restrictions may apply.
Cycloserine					
Cap 250 mg	5,185	\$67,120	\$12.9450	C H 1%	Current restrictions may apply. Unit subsidy and cost shown is weighted.
Darunavir					
<u>Tab 400 mg</u>	93,157	\$520,126	\$5.5833	C H 1%	Current restrictions may apply.
<u>Tab 600 mg</u>	33,847	\$268,519	\$7.9333	C H 1%	Current restrictions may apply.
Doxycycline					
Inj 100 mg per 20 ml				H 1%	
Tab 20 mg - 50 mg	335,923	\$32,474	\$0.0967	C H 1%	Note units and unit price expressed is for the 50 mg presentation.
Erythromycin Ethyl Succinate					
Grans for oral liq 200 mg per 5 ml	2,915,052	\$145,753	\$0.0500	C H 1%	Preference may be given to products which include a measuring device.
Grans for oral liq 400 mg per 5 ml	3,561,611	\$241,121	\$0.0677	C H 1%	Preference may be given to products which include a measuring device.
Tab 400 mg	3,217,984	\$545,448	\$0.1695	C H 1%	
Erythromycin Lactobionate					
Inj 1 g	223	\$3,568	\$16.0000	C H 1%	
Ethambutol hydrochloride					
Tab 100 mg	33,493	\$28,714	\$0.8573	C H 1%	Current restrictions may apply.
Tab 400 mg	124,390	\$109,596	\$0.8811	C H 1%	Current restrictions may apply.
Etravirine					
Tab 200 mg	38,896	\$499,165	\$12.8333#	C H 1%	Special Authority restrictions may apply.
Flucloxacillin sodium					
<u>Inj 250 mg</u>	120	\$108	\$0.9000	C H 1%	
<u>Inj 500 mg</u>	1,474	\$1,386	\$0.9400	C H 1%	
<u>Inj 1 g</u>	4,696	\$4,903	\$1.0440	C H 1%	
Fluconazole					
Powder for oral suspension 10 mg per ml	22,615	\$63,645	\$2.8143	C H 1%	
<u>Cap 50 mg</u>	101,639	\$7,586	\$0.0746	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Fluconazole					
Cap 150 mg	68,861	\$22,724	\$0.3300	C H 1%	
Cap 200 mg	62,042	\$11,256	\$0.1814	C H 1%	
Flucytosine					
Cap 500 mg				H 1%	Current restrictions may apply.
Foscarnet sodium					
Inj 24 mg per ml, 250 ml				H 1%	Current restrictions may apply.
Fosfomycin					
Powder for oral solution, 3 g sachet				H 1%	Current restrictions may apply.
Fusidic acid					
Tab 250 mg	11,023	\$31,691	\$2.8750	C H 1%	Current restrictions may apply.
Gentamicin Sulphate					
Inj 10 mg per ml	1,802	\$9,010	\$5.0000	C H 1%	
Inj 40 mg per ml, 2 ml	13,495	\$8,097	\$0.6000	C H 1%	
Hexamine hippurate					
Tab 1 g	588,841	\$108,347	\$0.1840	C H 1%	
Ketoconazole					
Tab 200 mg	1,650			PCT C H 1%	Current restrictions may apply.
Lamivudine					
Tab 300 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.
Tab 100 mg	167,182	\$25,077	\$0.1500	C H 1%	Special Authority restrictions may apply.
Tab 150 mg	24,705	\$21,617	\$0.8750	C H 1%	Special Authority restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.
Lopinavir with ritonavir					
Tab 100 mg with ritonavir 25 mg			\$3.0625	C H 1%	Special Authority restrictions may apply.
Tab 200 mg with ritonavir 50 mg	49,192	\$189,799	\$3.8583	C H 1%	Special Authority restrictions may apply.
Mebendazole					
Tab 100 mg	62,189	\$62,682	\$1.0079	C H 1%	
Meropenem					
Inj 500 mg				H 1%	Current restrictions may apply.
Inj 1 g				H 1%	Current restrictions may apply.
Metronidazole					
Inj 5 mg per ml, 100 ml				H 1%	Preference for a bag presentation with space to add another antibiotic.
Oral liq 200 mg per 5 ml	240,445	\$60,111	\$0.2500	C H 1%	
Suppos 500 mg	6,291	\$15,401	\$2.4480	C H 1%	
Tab 200 mg	406,330	\$42,462	\$0.1045	C H 1%	
Tab 400 mg	1,978,110	\$359,027	\$0.1815	C H 1%	
Nitazoxanide					
Tab 500 mg				C H 1%	Current restrictions may apply. Not currently listed in Section B of the Pharmaceutical Schedule.
Oral 100 mg per 5 ml				H 1%	Current restrictions may apply.
Nitrofurantoin					
Tab modified-release				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Norfloxacin					
Tab 400 mg	116,182	\$156,846	\$1.3500	C H 1%	
Paromomycin					
Cap 250 mg	1,672	\$13,167	\$7.8750	C H 1%	Special Authority restrictions may apply.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Piperacillin with tazobactam					
Inj 4 g with tazobactam 500 mg				H 1%	Current restrictions may apply. PHARMAC will consider other 8:1 (piperacillin:tazobactam) presentations if cost effective.
Pivmecillinam					
Tab 200 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.
Praziquantel					
Tab 600 mg	822	\$6,983	\$8.5000	C H 1%	
Primaquine phosphate					
Tab 7.5 - 15 mg	484	\$1,011	\$2.0893	C H 1%	Tab 7.5 mg is currently listed in Section B of the Pharmaceutical Schedule. Units shown are for tab 7.5 mg. Special Authority restrictions may apply. There may be a preference for a scored tablet.
Procaine penicillin					
Inj 1.5 mega u	1,141	\$28,183	\$24.7000	C H 1%	
Protionamide					
Tab 250 mg	4,194	\$12,792	\$3.0500	C H 1%	Current restrictions may apply.
Pyrazinamide					
Tab 500 mg	110,215	\$65,027	\$0.5900	C H 1%	Current restrictions may apply. There may be a preference for a scored tablet or a tablet that is dispersible in water.
Pyrimethamine					
Tab 25 mg	1,594	\$1,178	\$0.7390	C H 1%	Current restrictions may apply. There may be preference for a scored tablet or tablet that is dispersible in water.
Quinine dihydrochloride					
Inj 600 mg				H 1%	Current restrictions may apply.
Rifabutin					
Cap 150 mg	7,187	\$65,881	\$9.1667	C H 1%	
Rifampicin					
Cap 150 mg	87,288	\$48,663	\$0.5575	C H 1%	Current restrictions may apply.
Cap 300 mg	161,524	\$187,772	\$1.1625	C H 1%	Current restrictions may apply.
Inj 600 mg				H 1%	Current restrictions may apply.
Oral liq 100 mg per 5 ml	65,874	\$13,175	\$0.2000	C H 1%	Current restrictions may apply.
Streptomycin sulphate					
Inj 400 mg per ml, 2.5 ml				H 1%	Current restrictions may apply.
Sulfadiazine Sodium					
Tab 500 mg	368	\$3,570	\$9.7000	C H 1%	Current restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.
Terbinafine					
Tab 250 mg	2,085,783	\$198,149	\$0.0950	C H 1%	
Tetracycline					
Cap 500 mg	27,543	\$42,233	\$1.5333	C H 1%	Current restrictions may apply.
Tab 250 mg				H 1%	
Ticarcillin with clavulanic acid					
Inj 3 g with clavulanic acid 0.1 mg vial				H 1%	Current restrictions may apply.
Tobramycin					
Powder BP				H 1%	Current restrictions may apply.
Solution for inhalation 60 mg per ml, 5 ml	21,981	\$863,539	\$39.2857 #	C H 1%	A confidential rebate applies. Current restrictions may apply.
Inj 100 mg per ml, 5 ml				H 1%	Current restrictions may apply.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Infections

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Trimethoprim					
Line Item					
Tab 100 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Vancomycin hydrochloride					
Inj 500 mg	6,863	\$16,265	\$2.3700	C H 1%	Current restrictions may apply.

Musculoskeletal System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Allopurinol					
Line Item					
Tab 100 mg	24,840,484	\$225,552	\$0.0091	C H 1%	Preference for a scored tablet.
Tab 300 mg	18,222,228	\$377,200	\$0.0207	C H 1%	Preference for a scored tablet.
Baclofen					
Inj 0.05 mg per ml, 1 ml			\$11.5500	C H 1%	
Capsaicin (current access)					
Crm 0.025%	1,604,450	\$363,087	\$0.2263 #	C H 1%	Current restrictions may apply. Please note the widening of access refers to the crm 0.075% presentation only.
Capsaicin (widened access)					
Crm 0.025%	1,604,450	\$363,087	\$0.2263 #	C H 1%	Current restrictions may apply. Please note the widening of access refers to the crm 0.075% presentation only. This tender item is listed under widened access for the purpose of aggregate bidding in the e-portal.
Diclofenac sodium					
Inj 25 mg per ml, 3 ml	26,367	\$69,609	\$2.6400	C H 1%	
Suppos 12.5 mg	6,197	\$1,264	\$0.2040	C H 1%	
Suppos 25 mg	5,132	\$1,252	\$0.2440	C H 1%	
Suppos 50 mg	75,572	\$31,891	\$0.4220	C H 1%	
Suppos 100 mg	107,910	\$75,537	\$0.7000	C H 1%	
Ibuprofen					
Tab 200 mg	55,371,352	\$648,399	\$0.0117	C H 1%	
Leflunomide					
Tab 10 mg	543,182	\$52,509	\$0.0967	C H 1%	
Tab 20 mg	724,984	\$70,084	\$0.0967	C H 1%	
Neostigmine metisulfate					
Inj 2.5 mg per ml, 1 ml	11,139	\$21,832	\$1.9600	C H 1%	
Pamidronate disodium					
Inj 3 mg per ml, 10 ml	334	\$1,997	\$5.9800	C H 1%	
Inj 6 mg per ml, 10 ml	29	\$436	\$15.0200	C H 1%	
Inj 9 mg per ml, 10 ml	83	\$1,415	\$17.0500	C H 1%	
Suxamethonium chloride					
Inj 50 mg per ml, 2 ml				H 1%	There may be a preference for a pre-filled syringe.

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Alfentanil					
Line Item					
Inj 0.5 mg per ml, 2 ml ampoule				H 1%	
Amisulpride					
Oral liq	16,187	\$17,679	\$1.0922	C H 1%	Units and subsidy shown are for oral liq 100 mg per ml presentation.
Amitriptyline					
Tab 10 mg	21,155,458	\$414,647	\$0.0196	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Amitriptyline					
Tab 25 mg	7,671,899	\$116,613	\$0.0152	C H 1%	
Tab 50 mg	2,686,424	\$67,429	\$0.0251	C H 1%	
Benzatropine Mesylate					
Inj 1 mg per ml, 2 ml	1,517	\$28,823	\$19.0000	C H 1%	
Bethahistine dihydrochloride					
Tab 16 mg	3,382,438	\$116,356	\$0.0344	C H 1%	
Bupivacaine hydrochloride					
Inj 2.5 mg per ml, 20 ml ampoule				H 1%	
Inj 5 mg per ml, 20 ml ampoule				H 1%	
Inj 1.25 mg per ml, 100 ml bag				H 1%	
Inj 1.25 mg per ml, 200 ml bag				H 1%	
Inj 1.25 mg per ml, 500ml bag				H 1%	
Inj 2.5 mg per ml, 100 ml bag				H 1%	
Inj 2.5 mg per ml, 200 ml bag				H 1%	
Inj 5 mg per ml, 4 ml				H 1%	
Inj 0.25%, 20 ml sterile pack				H 1%	
Inj 0.5%, 10 ml sterile pack				H 1%	
Inj 0.5%, 20 ml sterile pack				H 1%	
Bupropion hydrochloride					
Tab modified-release 150 mg	2,330,945	\$854,687	\$0.3667	C H 1%	
Capsaicin (current access)					
Crm 0.075%	347,580	\$96,551	\$0.2778	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Capsaicin (widened access)					
Crm 0.075%				C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Clobazam					
Liq				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Codeine phosphate					
Tab 15 mg	10,532,470	\$605,617	\$0.0575	C H 1%	
Tab 30 mg	25,125,868	\$1,708,559	\$0.0680	C H 1%	
Tab 60 mg	1,665,297	\$224,815	\$0.1350	C H 1%	
Dexmedetomidine hydrochloride					
Inj 100 mcg per ml, 2 ml vial				+ H 1%	Patent may exist for this product.
Diazepam					
Tab 2 mg	2,961,780	\$89,150	\$0.0301	C H 1%	There may be a preference for a scored tablet.
Tab 5 mg	4,355,885	\$140,956	\$0.0324	C H 1%	
Disulfiram					
Tab 200 mg	409,347	\$309,343	\$0.7557	C H 1%	
Donepezil hydrochloride					
Tab 5 mg	1,239,193	\$59,754	\$0.0482	C H 1%	
Tab 10 mg	1,127,992	\$83,223	\$0.0738	C H 1%	
Dosulepin [Dothiepin] Hydrochloride					
Cap 25 mg	2,478,283	\$159,849	\$0.0645	C H 1%	
Tab 75 mg	894,920	\$100,142	\$0.1119	C H 1%	
Doxepin hydrochloride					
Cap 10 mg	1,137,560	\$71,666	\$0.0630	C H 1%	
Cap 25 mg	1,313,518	\$90,107	\$0.0686	C H 1%	
Cap 50 mg	663,982	\$56,770	\$0.0855	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Escitalopram					
Tab 10 mg	10,418,137	\$412,975	\$0.0396	C H 1%	There may be a preference for a scored tablet.
Tab 20 mg	3,883,752	\$263,551	\$0.0679	C H 1%	
Fentanyl					
Patches 100 mcg per hour	31,214	\$71,168	\$2.2800	C H 1%	
Patches 12.5 mcg per hour	194,227	\$114,594	\$0.5900	C H 1%	
Patches 25 mcg per hour	151,062	\$110,577	\$0.7320	C H 1%	
Patches 50 mcg per hour	62,028	\$82,497	\$1.3300	C H 1%	
Patches 75 mcg per hour	17,633	\$32,621	\$1.8500	C H 1%	
Flupenthixol Decanoate					
Inj 100 mg per ml, 1 ml	8,044	\$65,752	\$8.1740	C H 1%	
Inj 20 mg per ml, 1 ml	3,823	\$10,047	\$2.6280	C H 1%	
Inj 20 mg per ml, 2 ml	4,438	\$18,551	\$4.1800	C H 1%	
Granisetron					
Inj 1 mg per ml				H 1%	
Imipramine Hydrochloride					
Tab 10 mg	800,985	\$87,788	\$0.1096	C H 1%	
Tab 25 mg	433,685	\$76,329	\$0.1760	C H 1%	
Lacosamide (current access)					
Inj 10 mg per ml, 20 ml				H 1%	
Tab 50 mg	202,558	\$362,289	\$1.7886	C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.
Tab 100 mg	130,316	\$465,970	\$3.5757	C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.
Tab 150 mg	35,532	\$190,604	\$5.3643	C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.
Tab 200 mg	90,383	\$646,481	\$7.1527	C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.
Lacosamide (widened access)					
Tab 50 mg				C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. Widened access would result in a change from sixth to fifth line treatment. Refer to Schedule 7 for additional special terms.
Tab 100 mg				C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. Widened access would result in a change from sixth to fifth line treatment. Refer to Schedule 7 for additional special terms.
Tab 150 mg				C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. Widened access would result in a change from sixth to fifth line treatment. Refer to Schedule 7 for additional special terms.
Tab 200 mg				C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. Widened access would result in a change from sixth to fifth line treatment. Refer to Schedule 7 for additional special terms.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Levodopa with Carbidopa					
<u>Tab 100 mg with carbidopa 25 mg</u>	8,765,447	\$1,575,151	\$0.1797	C H 1%	Longer transition periods may apply to this product.
<u>Tab 250 mg with carbidopa 25 mg</u>	381,297	\$124,570	\$0.3267	C H 1%	Longer transition periods may apply to this product.
<u>Tab long-acting 200 mg with carbidopa 50 mg</u>	1,719,226	\$638,692	\$0.3715	C H 1%	Longer transition periods may apply to this product. Pharmacokinetic data required.
Lidocaine [Lignocaine]					
Crn 4%	420	\$425	\$1.0125	C H 1%	Current restrictions may apply. Unit subsidy and cost shown is weighted.
Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride					
<u>Soln 4% with adrenaline 0.1 % and tetracaine hydrochloride 0.5%, 5 ml syringe</u>				H 1%	
Lidocaine [lignocaine] hydrochloride with phenylephrine hydrochloride					
Nasal spray 5% with phenylephrine hydrochloride 0.5%				H 1%	
Lithium carbonate					
Cap (immediate-release) 250 mg	1,875,606	\$176,682	\$0.0942	C H 1%	
Tab (immediate-release) 250 mg	1,626,076	\$111,549	\$0.0686	C H 1%	
Tab long-acting 400 mg	1,866,078			C H 1%	
Maprotiline Hydrochloride					
Tab 25 mg	48,225	\$12,085	\$0.2506	C H 1%	
Tab 75 mg	2,251	\$1,576	\$0.7003	C H 1%	
Melatonin					
Tab 3 mg				H 1%	Current restrictions may apply.
Tab modified-release 2 mg	2,579,653	\$2,426,602	\$0.9407 #	C H 1%	Current restrictions may apply.
Mepivacaine hydrochloride					
Inj 3%, 1.8ml dental cartridge				H 1%	
Inj 3%, 2.2ml dental cartridge				H 1%	
Metoclopramide hydrochloride					
Oral liq 5 mg per 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Tab 10 mg</u>	5,656,088	\$73,529	\$0.0130	C H 1%	
Morphine					
<u>Inj 1 mg per ml, 10 ml syringe</u>				H 1%	Morphine sulphate inj 1 mg per ml, 10 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
<u>Inj 1 mg per ml, 100 ml bag</u>				H 1%	Morphine sulphate inj 1 mg per ml, 100 ml bag is currently listed in Section H of the Pharmaceutical Schedule.
Inj 1 mg per ml, 2 ml syringe				H 1%	Morphine sulphate inj 1 mg per ml, 2 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
<u>Inj 1 mg per ml, 50 ml syringe</u>				H 1%	Morphine sulphate inj 1 mg per ml, 50 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
<u>Inj 10 mg per ml, 1 ml</u>	213,500	\$190,869	\$0.8940	C H 1%	Units and subsidy shown are for morphine sulphate inj 10 mg per ml, 1 ml.
Inj 10 mg per ml, 100 mg cassette				H 1%	Morphine sulphate inj 10 mg per ml, 100 ml cassette is currently listed in Section H of the Pharmaceutical Schedule.
Inj 10 mg per ml, 100 ml bag				H 1%	Morphine sulphate inj 10 mg per ml, 100 ml bag is currently listed in Section H of the Pharmaceutical Schedule.
<u>Inj 15 mg per ml, 1 ml</u>	5,080	\$4,836	\$0.9520	C H 1%	Units and subsidy shown are for morphine sulphate inj 15 mg per ml, 1 ml.
Inj 2 mg per ml, 30 ml syringe				H 1%	Morphine sulphate inj 2 mg per ml, 30 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Morphine					
Inj 200 mcg in 0.4 ml syringe				H 1%	Morphine sulphate inj 200 mcg in 0.4 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
<u>Inj 30 mg per ml, 1 ml ampoule</u>	54,816	\$67,862	\$1.2380	C H 1%	Units and subsidy shown are for morphine sulphate inj 30 mg per ml, 1 ml ampoule.
Inj 300 mcg in 0.3 ml syringe				H 1%	Morphine sulphate inj 300 mcg in 0.3 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.
Inj 80 mg per ml	15,813	\$135,106	\$8.5440	C H 1%	Units and subsidy shown are for morphine tartrate inj 80 mg per ml, 1.5 ml ampoule.
<u>Tab immediate-release 10 mg</u>	3,300,436	\$924,122	\$0.2800	C H 1%	May be a preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 10 mg.
<u>Tab immediate-release 20 mg</u>	715,695	\$395,064	\$0.5520	C H 1%	May be a preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 20 mg.
Naltrexone hydrochloride					
<u>Tab 50 mg</u>	201,243	\$754,995	\$3.7517	C H 1%	Current restrictions may apply.
Olanzapine					
<u>Orodispersible tab 5 mg</u>	324,772	\$14,498	\$0.0446	C H 1%	
<u>Orodispersible tab 10 mg</u>	497,365	\$36,412	\$0.0732	C H 1%	
<u>Tab 2.5 mg</u>	1,737,142	\$39,711	\$0.0229	C H 1%	
<u>Tab 5 mg</u>	2,293,670	\$94,201	\$0.0411	C H 1%	
<u>Tab 10 mg</u>	2,796,732	\$164,811	\$0.0589	C H 1%	
Ondansetron					
<u>Tab disp 4 mg</u>	2,696,769	\$256,193	\$0.0950	C H 1%	
<u>Tab disp 8 mg</u>	1,209,514	\$172,961	\$0.1430	C H 1%	
Oxazepam					
<u>Tab 10 mg</u>	698,205	\$43,079	\$0.0617	C H 1%	
<u>Tab 15 mg</u>	216,524	\$18,469	\$0.0853	C H 1%	
Paliperidone (one-monthly depot injection)					
Inj 25 mg syringe	924	\$179,487	\$194.2500 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 50 mg syringe	2,652	\$721,211	\$271.9500 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 75 mg syringe	5,088	\$1,818,553	\$357.4200 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 100 mg syringe	12,067	\$5,250,593	\$435.1200 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 150 mg syringe	13,558	\$5,899,357	\$435.1200 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Paliperidone (three-monthly depot injection)					
Inj 175 mg syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Inj 250 - 300 mg syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Inj 350 mg syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Inj 500 mg or greater syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Palonosetron					
Inj 250 mcg				H 1%	Not currently listed in the Pharmaceutical Schedule.
Paracetamol					
<u>Tab 500 mg, blister pack</u>	321,927,226			C H 10%	
<u>Tab 500 mg, bottle pack</u>	38,824,793	\$245,373	\$0.0063	C H 10%	
<u>sole supply</u>					

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Paracetamol					
Inj 10 mg per ml, 100 ml				H 1%	
<u>Oral liq 120 mg per 5 ml</u>	59,671,499	\$319,243	\$0.0054	C H 20%	Preference may be given to products which include a measuring device.
<u>Oral liq 250 mg per 5 ml</u>	257,689,578	\$1,497,176	\$0.0058	C H 20%	Preference may be given to products which include a measuring device.
Paracetamol with codeine					
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	45,440,910	\$827,479	\$0.0182	C H 1%	
Paraldehyde					
Inj 5 ml	5	\$1,500	\$300.0000	C H 1%	
Pericyazine					
Tab 10 mg	158,174	\$70,311	\$0.4445	C H 1%	
Tab 2.5 mg	267,722	\$33,435	\$0.1249	C H 1%	
Pethidine hydrochloride					
Inj 5 mg per ml, 10 ml				H 1%	Preservative free desirable
Inj 10 mg per ml, 100 ml bag				H 1%	
Inj 10 mg per ml, 50 ml syringe				H 1%	
Inj 5 mg per ml, 100 ml bag				H 1%	
<u>Inj 50 mg per ml, 1 ml</u>	4,461	\$4,443	\$0.9960	C H 1%	
<u>Inj 50 mg per ml, 2 ml</u>	15,893	\$16,274	\$1.0240	C H 1%	
Phenelzine sulphate					
Tab 15 mg	97,065	\$114,536	\$1.1800	C H 1%	
Phenytoin Sodium					
Inj 50 mg per ml, 2 ml	591	\$10,476	\$17.7260	C H 1%	
Inj 50 mg per ml, 5 ml	542	\$14,517	\$26.7840	C H 1%	
Prochlorperazine					
<u>Tab 5 mg</u>	3,533,778	\$89,758	\$0.0254	C H 1%	
Quetiapine					
<u>Tab 100 mg</u>	3,747,041	\$143,624	\$0.0383	C H 1%	
<u>Tab 200 mg</u>	1,196,481	\$76,443	\$0.0639	C H 1%	
<u>Tab 25 mg</u>	21,780,013	\$433,204	\$0.0199	C H 1%	There may be a preference for a scored tablet.
<u>Tab 300 mg</u>	468,008	\$49,922	\$0.1067	C H 1%	
Rasagiline					
Tab 1 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Pricing should be similar to selegine.
Remifentanyl hydrochloride					
<u>Inj 1 mg</u>				H 1%	
<u>Inj 2 mg</u>				H 1%	
Risperidone					
Inj 25 mg vial	4,162	\$565,949	\$135.9800	C H 1%	Current restrictions may apply.
Inj 37.5 mg vial	5,578	\$996,844	\$178.7100	C H 1%	Current restrictions may apply.
Inj 50 mg vial	7,028	\$1,529,012	\$217.5600	C H 1%	Current restrictions may apply.
<u>Oral liquid 1 mg per ml</u>	359,850	\$91,881	\$0.2553	C H 1%	
<u>Tab 0.5 mg</u>	2,978,434	\$92,331	\$0.0310	C H 1%	
<u>Tab 1 mg</u>	2,129,800	\$73,116	\$0.0343	C H 1%	
<u>Tab 2 mg</u>	1,024,326	\$39,099	\$0.0382	C H 1%	
<u>Tab 3 mg</u>	416,418	\$17,352	\$0.0417	C H 1%	
<u>Tab 4 mg</u>	200,667	\$11,472	\$0.0572	C H 1%	
Rizatriptan					
<u>Tab orodispersible 10 mg</u>	1,727,121	\$302,816	\$0.1753	C H 1%	
Ropivacaine hydrochloride					
<u>Inj 2 mg per ml, 10 ml</u>				H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Nervous System

Chemical Name				DV	
Line Item	Units	Cost	Unit Subsidy	Limit	Comments
Ropivacaine hydrochloride					
<u>Inj 2 mg per ml, 20 ml</u>				H 1%	
<u>Inj 2 mg per ml, 100 ml</u>				H 1%	
<u>Inj 2 mg per ml, 200 ml</u>				H 1%	
<u>Inj 7.5 mg per ml, 10 ml</u>				H 1%	
<u>Inj 7.5 mg per ml, 20 ml</u>				H 1%	
<u>Inj 10 mg per ml, 10 ml</u>				H 1%	
<u>Inj 10 mg per ml, 20 ml</u>				H 1%	
Ropivacaine hydrochloride with fentanyl					
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag				H 1%	Sterile bag preferred.
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag				H 1%	Sterile bag preferred.
Temazepam					
<u>Tab 10 mg</u>	2,949,628	\$149,841	\$0.0508	C H 1%	
Tetracaine [amethocaine] hydrochloride					
Gel 4%				H 1%	
Tramadol hydrochloride					
Oral soln 10 mg per ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Inj 10 mg per ml, 100 ml bag				H 1%	
<u>Cap 50 mg</u>	32,104,932	\$722,361	\$0.0225	C H 1%	
<u>Inj 50 mg per ml, 1 ml</u>				H 1%	
<u>Inj 50 mg per ml, 2 ml</u>				H 1%	
<u>Tab sustained-release 100 mg</u>	4,932,239	\$382,249	\$0.0775	C H 1%	
<u>Tab sustained-release 150 mg</u>	456,866	\$47,971	\$0.1050	C H 1%	
<u>Tab sustained-release 200 mg</u>	357,486	\$49,154	\$0.1375	C H 1%	
Tranylcypromine Sulphate					
Tab 10 mg	200,560	\$92,017	\$0.4588	C H 1%	
Triazolam					
Tab 125 mcg	1,747,421	\$89,118	\$0.0510	C H 1%	
Tab 250 mcg	1,493,668	\$61,240	\$0.0410	C H 1%	
Zolmitriptan					
Nasal Spray				C H 1%	Not currently listed in the Pharmaceutical Schedule. May be subject to Special Authority restrictions.
Zopiclone					
Tab 3.75 mg (pack size 30 tabs or less)				H 1%	Not currently listed on the Pharmaceutical Schedule.
Tab 7.5 mg (pack size 30 tabs or less)				H 1%	Tablets should be scored.
Zuclopenthixol Acetate					
Inj 50 mg per ml, 1 - 2 ml				H 1%	
Zuclopenthixol Decanoate					
Inj 200 mg per ml	28,568	\$113,129	\$3.9600	C H 1%	
Inj 500 mg per ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Zuclopenthixol hydrochloride					
Tab 10 mg	198,665	\$62,480	\$0.3145	C H 1%	

Oncology Agents and Immunosuppressants

Chemical Name				DV	
Line Item	Units	Cost	Unit Subsidy	Limit	Comments
Anastrozole					
<u>Tab 1 mg</u>	836,608	\$140,550	\$0.1680	C H 1%	
Bicalutamide					
<u>Tab 50 mg</u>	588,300	\$79,838	\$0.1357	C H 1%	
<u>sole supply</u>					

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Calcium folinate						
Tab 15 mg	15,421	\$160,779	\$10.4260		PCT C H 1%	
Docetaxel						
<u>Inj 20 mg</u>					PCT H 1%	Preference for products where stability data >48 hours post-compounding.
<u>Inj 80 mg</u>					PCT H 1%	Preference for products where stability data >48 hours post-compounding.
Erlotinib hydrochloride						
Tab 100 mg	15,260	\$388,628	\$25.4667	+	C H 1%	Current restrictions may apply.
Tab 150 mg	22,313	\$852,357	\$38.2000	+	C H 1%	Current restrictions may apply.
Etoposide						
Inj 20 mg per ml, 5 ml		\$11,091	\$7.9000		PCT C H 1%	PHARMAC reserves the right to award a tender for the whole market for either etoposide or etoposide phosphate.
Etoposide phosphate						
Inj 100 mg (of etoposide base)					PCT H 1%	Preference for products where stability data >48 hours post-compounding. PHARMAC reserves the right to award a tender for the whole market for either etoposide or etoposide phosphate.
Exemestane						
<u>Tab 25 mg</u>	362,963	\$175,431	\$0.4833		C H 1%	
Fulvestrant						
Inj 250 mg per ml				+	C H 1%	Not currently listed in the Pharmaceutical Schedule.
Gefitinib						
Tab 250 mg				+	C H 1%	Not currently listed in the Pharmaceutical Schedule. Current restrictions may apply.
Gemcitabine hydrochloride						
Inj 1 g					PCT H 1%	
Hydroxyurea						
Cap 500 mg	1,180,903	\$375,055	\$0.3176		PCT C H 1%	
Imatinib mesilate						
<u>Cap 400 mg</u>	68,920	\$453,723	\$6.5833 #		C H 1%	For non-GIST indications only.
<u>Cap 100 mg</u>	194,035	\$316,923	\$1.6333 #		C H 1%	For non-GIST indications only.
Methotrexate						
<u>Inj 100 mg per ml, 50 ml</u>		\$68,711	\$79.9900		PCT C H 1%	Preference for products where stability data >48 hours post-compounding.
Mitomycin C						
Inj 2 mg - 5 mg					PCT H 1%	Units and subsidy shown are per inj 5 mg presentation.
Inj 10 mg - 20 mg					PCT H 1%	Not currently listed on the Pharmaceutical Schedule.
Octreotide (somatostatin analogue)						
<u>Inj 50 mcg per ml, 1 ml</u>	5,154	\$31,584	\$6.1280		C H 1%	
<u>Inj 100 mcg per ml, 1 ml</u>	16,890	\$63,133	\$3.7380		C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	4,151	\$60,184	\$14.5000		C H 1%	
Paclitaxel						
<u>Inj 30 mg</u>					PCT H 1%	Preference for products where stability data >48 hours post-compounding.
<u>Inj 100 mg</u>					PCT H 1%	Preference for products where stability data >48 hours post-compounding.
Inj 150 mg					PCT H 1%	
<u>Inj 300 mg</u>					PCT H 1%	Preference for products where stability data >48 hours post-compounding.
Tamoxifen citrate						
<u>Tab 10 mg</u>	37,721	\$7,387	\$0.1958		C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Oncology Agents and Immunosuppressants

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Tamoxifen citrate					
<u>Tab 20 mg</u>	1,890,447	\$176,435	\$0.0933	C H 1%	
Thiotepa					
Inj 100 mg				PCT C H 1%	
Inj 15 mg				PCT C H 1%	

Respiratory System and Allergies

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Aminophylline					
<u>Inj 25 mg per ml, 10 ml</u>	1,522	\$37,858	\$24.8740	C H 1%	
Bee venom allergy treatment					
Inj with diluent	281	\$85,705	\$305.0000	C H 1%	
Maintenance kit	7	\$1,995	\$285.0000	C H 1%	
Budesonide					
Nebuliser soln 250 mcg per ml, 2 ml ampoule				H 1%	
<u>Metered aqueous nasal spray, 50 mcg per dose</u>	3,292,200	\$42,634	\$0.0130	C H 1%	
<u>Metered aqueous nasal spray, 100 mcg per dose</u>	16,498,200	\$236,749	\$0.0144	C H 1%	
Nebuliser soln, 500 mcg per ml, 2 ml				H 1%	
Chlorpheniramine Maleate					
Inj 10 mg per ml				H 1%	
Oral liq 2 mg per 5 ml	2,765,123	\$44,574	\$0.0161	C H 1%	
Dextrochlorpheniramine Maleate					
Oral liq 2 mg per 5 ml	8,780	\$155	\$0.0177	C H 1%	Funding restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.
Tab 2 mg	144,440	\$7,294	\$0.0505 *	C H 1%	Funding restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.
Fexofenadine					
Tab 120 mg	145,558	\$68,989	\$0.4740 *	C H 1%	
Tab 180 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 60 mg	68,166	\$14,792	\$0.2170	C H 1%	
Ipratropium Bromide					
<u>Aqueous nasal spray, 0.03%</u>	818,595	\$251,579	\$0.3073	C H 1%	
Paper wasp venom					
Inj with diluent for extract	17	\$5,185	\$305.0000	C H 1%	Current restrictions may apply.
Treatment kit	8	\$2,440	\$305.0000	C H 1%	Special Authority restrictions may apply.
Pirfenidone					
Cap 267 mg	260,770	\$3,520,395	\$13.5000 #	C H 1%	
Poractant Alfa					
Soln 120 mg per 1.5 ml vial				H 1%	
Soln 240 mg per 3 ml vial				H 1%	
Pseudoephedrine Hydrochloride					
Tab 60 mg				H 1%	
Sodium cromoglicate					
Nasal spray, 4%				H 1%	
Talc					
Powder				H 1%	
Soln (slurry) 100 mg per ml, 50 ml				H 1%	
Xylometazoline hydrochloride					
Aqueous nasal spray 0.05%				H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Respiratory System and Allergies

Chemical Name			Unit Subsidy		DV Limit	Comments
Line Item	Units	Cost				
Xylometazoline hydrochloride						
Aqueous nasal spray 0.1%					H 1%	
Nasal drops 0.05%					H 1%	
Nasal drops 0.1%					H 1%	
Yellow jacket wasp venom						
Inj with diluent for extract	14	\$4,270	\$305.0000		C H 1%	
Treatment kit	1	\$305	\$305.0000		C H 1%	

Sensory Organs

Chemical Name			Unit Subsidy		DV Limit	Comments
Line Item	Units	Cost				
Acetazolamide						
Tab 250 mg	674,232	\$114,822	\$0.1703		C H 1%	
Atropine sulphate						
Eye drops 1%	116,370	\$134,678	\$1.1573		C H 1%	
Betaxolol hydrochloride						
Eye drops 0.25%	17,435	\$41,147	\$2.3600		C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
Eye drops 0.5%	7,990	\$11,985	\$1.5000		C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
Carmellose sodium						
Eye drops 0.5%					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Eye drops 1%					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Ciprofloxacin						
Ear drops 0.3%					C H 1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
Cyclopentolate hydrochloride						
Eye drops 1%	81,210	\$47,427	\$0.5840		C H 1%	
Flumetasone pivalate with clioquinol						
Ear drops 0.02% with clioquinol 1%	40,125	\$23,861	\$0.5947		C H 1%	
Fluorometholone						
Eye drops 0.1%	155,570	\$94,140	\$0.6051		C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Unit subsidy shown is weighted and expressed as "per ml"
Framycetin sulphate						
Ear/Eye drops 0.5%	22,152	\$11,436	\$0.5163		C H 1%	
Hypromellose						
Eye drops 0.3%	3,207,270	\$491,771	\$0.1533		C H 1%	Will consider bids for products with or without dextran. Note units and unit subsidy are expressed for a product with dextran 0.1%.
Eye drops 0.5%	49,530	\$6,604	\$0.1333		C H 1%	
Levocabastine						
Eye drops 0.5 mg per ml	94,116	\$204,938	\$2.1775		C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml

SCHEDULE TWO: PRODUCTS TO BE TENDERED (draft, by therapeutic group)

Sensory Organs

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Paraffin liquid with soft white paraffin						
Eye oint with soft white paraffin	80,378			C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Paraffin liquid with wool fat liquid						
Eye oint 3% with wool fat liq 3%	231,909	\$240,522	\$1.0371	C H 1%		
Polyvinyl alcohol						
Eye drops 1.4%	498,855	\$87,135	\$0.1747	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml	
Eye drops 3%	261,525	\$64,160	\$0.2453	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml	
Sodium fusidate [fusidic acid]						
Eye drops 1%	303,875	\$321,500	\$1.0580	C H 1%	Units and unit subsidy expressed as "per ml".	
Timolol maleate						
<u>Eye drops 0.25%</u>	149,600	\$42,786	\$0.2860	C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market.	
<u>Eye drops 0.5%</u>	127,025	\$36,329	\$0.2860	C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market.	
Travoprost						
<u>Eye drops 0.004%</u>	49,739	\$223,633	\$4.4961	C H 1%	This product is currently subject to a confidential rebate. For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml.	
Triamcinolone acetonide with gramicidin, neomycin and nystatin						
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	582,720	\$400,911	\$0.6880	C H 1%		

Various

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Chlorhexidine with ethanol						
Soln 2% with ethanol 70%, non-staining (pink) (pack size less than 50 ml)				H 1%		
Soln 2% with ethanol 70%, non-staining (pink) 100 ml				H 1%		
Soln 2% with ethanol 70%, staining (red) (pack size less than 50 ml)				H 1%		
Soln 2% with ethanol 70%, staining (red) 100 ml				H 1%		